Biotalys starts field testing for biofungicide
Belgian AgTech specialist Biotalys BV an Agricultural Technology (AgTech) company has initiated field trials for BioFun-6, the company’s second llama-antibody-mimicking biofungicide program.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Three companies launch gene therapy alliance for eye diseases
/in News/by Thomas GabrielczykAI specialist WhiteLab Genomics, the Vision Institute, and IT expert ADLIN Science, have entered into a strategic partnership aimed at developing new AAV vectors targetting retinal dystrophies.
Obesity: reseachers switch on brown fat cells
/in News/by Thomas GabrielczykA German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.
Klineo raises €2m to speed up access to cancer trials
/in News/by Thomas GabrielczykParis-based Klineo SAS has raised €2M to speed up access to clinical trials for oncology patients using an AI platform.<br />`<br /><br />
Locate Bio Ltd raises £9.2m venture capital
/in News/by Thomas GabrielczykUniversity Nottingham spin out Locate Bio Ltd has added £9.2m venture financing led by Mercia Ventures and Business Growth Fund to its £16.2m raised before.
Electrochaea sells biomethane reactor to Again A/S
/in News/by Thomas GabrielczykArchaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S.
Flindr Therapeutics BV secures €20m Series A financing
/in News/by Thomas GabrielczykOss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Nordic Bioproducts Group opens its first production facility
/in News/by Thomas GabrielczykFinnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology
Swiss Biotech Report reporting record turnover
/in News/by Thomas GabrielczykThe Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn.<span style="mso-ansi-language:EN-US" lang="EN-US"> Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and […]
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
/in News/by Thomas GabrielczykIpsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.